Abstract：
Allergic conjunctivitis (AC) is a common condition resulting from exposure to allergens such as pollen, animal dander, or mold. It is typically mediated by allergen-induced crosslinking of immunoglobulin E attached to receptors on primed conjunctival mast cells, which results in mast cell degranulation and histamine release, as well as the release of lipid mediators, cytokines, and chemokines. The clinical result is conjunctival hyperemia, tearing, intense itching, and chemosis. Refractory and chronic cases can result in ocular surface complications that may be vision threatening. Patients who experience even mild forms of this disease report an impact on their quality of life. Current treatment options range from non-pharmacologic therapies to ocular and systemic options. However, to adequately control AC, the use of multiple agents is often required. As such, a precise understanding of the immune mechanisms responsible for this ocular surface inflammation is needed to support ongoing research for potential therapeutic targets such as chemokine receptors, cytokine receptors, non-receptor tyrosine kinases, and integrins. This review utilized several published articles regarding the current therapeutic options to treat AC, as well as the pathological and immune mechanisms relevant to AC. This review will also focus on cellular and molecular targets in AC, with particular emphasis on potential therapeutic agents that can attenuate the pathology and immune mechanisms driven by cells, receptors, and molecules that participate in the immunopathogenesis and immunopathology of AC.
摘要：
过敏性结膜炎（AC）是由于暴露于花粉等过敏原而导致的常见疾病，动物皮屑,或霉菌。它通常由过敏原诱导的免疫球蛋白E与引发的结膜肥大细胞上的受体连接的交联介导。导致肥大细胞脱粒和组胺释放，以及脂质介质的释放，细胞因子,和趋化因子.临床结果是结膜充血，撕裂,剧烈瘙痒,和化学.难治性和慢性病例可导致眼表并发症，可能威胁视力。经历这种疾病的轻度形式的患者报告对他们的生活质量有影响。目前的治疗选择范围从非药物疗法到眼部和全身选择。然而,为了充分控制交流电，通常需要使用多个代理。因此，需要精确了解导致这种眼表炎症的免疫机制，以支持正在进行的潜在治疗靶点如趋化因子受体的研究，细胞因子受体,非受体酪氨酸激酶，和整合素。这篇综述利用了几篇发表的文章，关于目前治疗AC的治疗选择，以及与AC相关的病理和免疫机制。本文还将重点关注AC中的细胞和分子靶标，特别强调可以减弱由细胞驱动的病理和免疫机制的潜在治疗剂，受体,以及参与AC的免疫病理和免疫病理的分子。
